RECRUITING

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Description

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Conditions

Lung CancerLung Cancer MetastaticBrain MetastasesNon Small Cell Lung Cancer
Talk to us

Related Conditions:

Lung CancerLung Cancer MetastaticBrain MetastasesNon Small Cell Lung Cancer

Study Overview

On this page

Study Details

Study overview

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Sacramento

The University of California Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Men and women age \>18 yrs
  • 2. Biopsy proven NSCLC with brain metastases (treated or untreated)
  • 3. Life-expectancy of ≥3 months in the opinion of the treating physician
  • 4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
  • 5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
  • 6. Ability to understand and willingness to sign a written informed consent document.
  • 7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
  • 8. \[18F\]-FDG PET/CT within 21 days of enrollment
  • 9. MRI brain within 21 days of enrollment
  • 10. Eastern Cooperative Oncology Group Performance Status ≤ 2
  • 11. Glomerular filtration rate (GFR) ≥ 60
  • 1. Pregnant or lactating women
  • 2. Prisoners
  • 3. Concurrent malignancy of a different histology that could confound imaging interpretation
  • 4. Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Julie L. Sutcliffe, PhD, PRINCIPAL_INVESTIGATOR, The Regents of the University of California (Davis)

Study Record Dates

2025-12-31